STOCK TITAN

Armistice and Steven Boyd Disclose 2.98M Shares of Orthofix

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting shared voting and dispositive power over 2,978,000 shares of Orthofix Medical Inc. common stock, equal to 7.54% of the class based on 39,494,265 shares outstanding. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and Mr. Boyd is the managing member of Armistice Capital. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Positive

  • 2,978,000 shares (7.54%) beneficially owned with shared voting and dispositive power reported
  • Clear disclosure that holdings are managed via Armistice Capital and held in ordinary course, with certification against intent to influence control

Negative

  • None.

Insights

TL;DR: Armistice reports a meaningful 7.54% stake in Orthofix with shared voting and dispositive power via its managed fund.

The filing discloses that Armistice Capital, acting as investment manager to its Master Fund, and Steven Boyd as managing member, exercise shared voting and dispositive authority over 2,978,000 Orthofix shares, representing 7.54% of outstanding shares. This is a material passive ownership disclosure that warrants monitoring for any changes but does not by itself indicate a control intent, as the filing affirms ordinary-course holdings and disclaims an intent to influence control.

TL;DR: The Schedule 13G/A shows passive, passive-manager ownership rather than an activist or control filing.

The report is filed under Schedule 13G/A and includes a certification that the securities were acquired and are held in the ordinary course of business and not to change control. The joint filing statement establishes shared responsibility for future amendments. Investors should note the shared voting/dispositive power structure between the manager and the fund.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

How many Orthofix (OFIX) shares does Armistice Capital report owning?

The filing reports 2,978,000 shares, representing 7.54% of the class.

Who holds voting and dispositive power over the reported OFIX shares?

Armistice Capital, LLC and Steven Boyd report shared voting and shared dispositive power over the 2,978,000 shares.

On what basis is the 7.54% ownership calculated?

The percentage is based on 39,494,265 shares outstanding as reported by the issuer for the period referenced in the filing.

Does the filing state an intent to influence control of Orthofix?

No; the filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

When was the Schedule 13G/A signed?

The signature block shows the filing was signed by Steven Boyd on 08/14/2025.
Orthofix Med Inc

NASDAQ:OFIX

OFIX Rankings

OFIX Latest News

OFIX Latest SEC Filings

OFIX Stock Data

622.11M
38.64M
2.76%
91.93%
4.6%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
LEWISVILLE